Prelude's Military Families Month campaign comes on the heels of the Department ... and they continue to lead the industry by building on these technologies by through development, research and ...

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated ... controlled trial (RCT), Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation.

Prelude Therapeutics Incorporated (PRLD) has been on a downward spiral lately with significant selling pressure. After ...

WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, has shared its third-quarter ...

Prelude Therapeutics ( (PRLD) ) has provided an announcement. Prelude Therapeutics announced its third quarter 2024 financial results, ...

Analyst Reni Benjamin from JMP Securities reiterated a Buy rating on Prelude Therapeutics (PRLD – Research Report) and keeping the price ...

Net sales of $502 million (+5% actual rates, +6% constant exchange rates, CER); diluted EPS of $0.44 and adjusted diluted EPS ...

Presented interim data from the ongoing Phase 1 dose escalation study of PRT3789, its first-in-class IV SMARCA2 degrader, ...

The EIT Community will be hosting the INNOVEIT Conference which will feature industry leaders like Inga Grieger, Katarzyna ...

On Thursday, Prelude Therapeutics Inc (PRLD) stock saw a decline, ending the day at $1.2 which represents a decrease of $-0.12 or -9.09% from the prior close of $1.32. The stock opened at $1.31 and ...

From St Thomas Church, Fifth Avenue, New York, on the eve of American Thanksgiving, with music by Hancock, Sebastian Forbes, ...

Prelude Therapeutics Inc (PRLD)股票已达到52周低点，交易价格为1.32美元，这家生物制药公司正面临着充满挑战的市场环境。这一最新价格水平反映出与之前时期相比的显著下跌，对投资者和利益相关者来说标志着一个令人担忧的里程碑。在过去一年中，PRLD的价值下降了21.01%，表明公司的增长前景面临着看跌情绪和潜在的不利因素。52周低点作为公司表现的关键指标，可能会促使公司重 ...